Evidence map›Paper›PMID 28867267›Full record

Trial reportThe lancet. HIV2017

Testing and linkage to HIV care in China: a cluster-randomised trial.

Zunyou Wu, Zhenzhu Tang, Yurong Mao, Paul Van Veldhuisen, Walter Ling, David Liu, Zhiyong Shen, Roger Detels, Guanghua Lan, Lynda Erinoff and 19 more

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in The lancet. HIV, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02084316 (Testing and Linkage to HIV Care in China), which is not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02084316 phase2 / phase3completednot on this map

Testing and Linkage to HIV Care in China: A Clustered Randomized Trial

TypeinterventionalSponsorUniversity of California, Los AngelesRan2014 to 2016Enrolled360ConditionsHIVArmsOne4All, Standard of Care
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Rapid initiation of antiretroviral therapy for people living with HIV.The Cochrane database of systematic reviews · 2019
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. The Enigma of the Human Immunodeficiency Virus (HIV) Epidemic in China.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Article
  16. Observational
  17. Article
  18. Review
  19. Nationwide Cohort Study of Antiretroviral Therapy Timing: Treatment Dropout and Virological Failure in China, 2011-2015.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019
    Observational
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors.

Zunyou WuThe National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China. Electronic address: wuzy@263.net.
Zhenzhu TangGuangxi Center of Disease Control and Prevention, Nanning, China.
Yurong MaoThe National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Paul Van VeldhuisenThe Emmes Corporation, Rockville, MD, USA.
Walter LingIntegrated Substance Abuse Programs, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
David LiuNational Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA.
Zhiyong ShenGuangxi Center of Disease Control and Prevention, Nanning, China.
Roger DetelsDepartment of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA, USA.
Guanghua LanGuangxi Center of Disease Control and Prevention, Nanning, China.
Lynda ErinoffNational Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA.
Robert LindbladThe Emmes Corporation, Rockville, MD, USA.
Diane GuThe National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Houlin TangThe National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Lian HuThe Emmes Corporation, Rockville, MD, USA.
Qiuying ZhuGuangxi Center of Disease Control and Prevention, Nanning, China.
Li LuThe Emmes Corporation, Rockville, MD, USA.
Neal OdenThe Emmes Corporation, Rockville, MD, USA.
Albert L HassonIntegrated Substance Abuse Programs, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Yan ZhaoThe National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Jennifer M McGooganThe National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Xianmin GeGuangxi Center of Disease Control and Prevention, Nanning, China.
Nanci ZhangThe National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Keming RouThe National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Jinhui ZhuGuangxi Center of Disease Control and Prevention, Nanning, China.
Hui WeiThe Bureau of HIV/AIDS Control, Guangxi Zhuang Autonomous Regional Health and Family Planning Commission, Nanning, China.
Cynthia X ShiThe National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Xia JinThe National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Jian LiThe National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Julio S G MontanerBC Center for Excellence in HIV/AIDS, University of British Columbia, Vancouver, BC, Canada.

Funding

The National Drug Abuse Treatment Clinical Trials NetworkU10DA013045 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LING, WALTER NMN · 1999 to 2015
$52.6M
NIDA NIH HHS U10 DA013045
6 · The paper itself

Abstract

backgroundMultistage, stepwise HIV testing and treatment procedures can result in lost opportunities to provide timely antiretroviral therapy (ART). Incomplete engagement of patients along the care cascade translates into high preventable mortality. We aimed to identify whether a structural intervention to streamline testing and linkage to HIV health care would improve testing completeness, ART initiation, and viral suppression and reduce mortality.

methodsWe did a cluster-randomised, controlled trial in 12 hospitals in Guangxi, China. All hospitals were required to be level 2A county general hospitals and ART delivery sites. We selected the 12 most similar hospitals in terms of structural characteristics, past patient caseloads, and testing procedures. Hospitals were randomly assigned (1:1) to either the One4All intervention or standard of care. Hospitals were randomised in a block design and stratified by the historical rate of testing completeness of the individual hospital during the first 6 months of 2013. We enrolled patients aged 18 years or older who were identified as HIV-reactive during screening in study hospitals, who sought inpatient or outpatient care in a study hospital, and who resided in the study catchment area. The One4All strategy incorporated rapid, point-of-care HIV screening and CD4 counts, and in-parallel viral load testing, to promote fast and complete diagnosis and staging and provide immediate ART to eligible patients. Participants in control hospitals received standard care services. All enrolled patients were assessed for the primary outcome, which was testing completeness within 30 days, defined as completion of three required tests and their post-test counselling. Safety assessments were hospital admissions for the first 90 days and deaths up to 12 months after enrolment. This trial is registered with ClinicalTrials.gov, number NCT02084316.

findingsBetween Feb 24 and Nov 25, 2014, we enrolled 478 patients (232 in One4All, 246 in standard of care). In the One4All group, 177 (76%) of 232 achieved testing completeness within 30 days versus 63 (26%) of 246 in the standard-of-care group (odds ratio 19·94, 95% CI 3·86-103·04, p=0·0004). Although no difference was observed between study groups in the number of hospital admissions at 90 days, by 12 months there were 65 deaths (28%) in the in the One4All group compared with 115 (47%) in the standard-of-care group (Cox proportional hazard ratio 0·44, 0·19-1·01, p=0·0531).

interpretationOur study provides strong evidence for the benefits of a patient-centred approach to streamlined HIV testing and treatment that could help China change the trajectory of its HIV epidemic, and help to achieve the goal of an end to AIDS.

fundingUS National Institute on Drug Abuse Clinical Trials Network and China's National Health and Family Planning Commission.

Indexed as

AdultAgedAntiretroviral Therapy, Highly ActiveChinaFemaleHIVHIV InfectionsHumansMaleMass ScreeningMiddle AgedPoint-of-Care SystemsViral LoadYoung Adult

Identifiers

PMID28867267
PMCPMC6639122

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.